We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Read MoreHide Full Article
Zoetis (ZTS - Free Report) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.09%. On the other hand, the Dow registered a gain of 1.18%, and the technology-centric Nasdaq increased by 1.03%.
Prior to today's trading, shares of the animal health company had lost 7.46% over the past month. This has lagged the Medical sector's loss of 2.76% and the S&P 500's loss of 0.71% in that time.
Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. In that report, analysts expect Zoetis to post earnings of $1.38 per share. This would mark year-over-year growth of 11.29%. Meanwhile, our latest consensus estimate is calling for revenue of $2.32 billion, up 4.98% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $5.91 per share and a revenue of $9.26 billion, demonstrating changes of +11.09% and +8.41%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.08% increase. At present, Zoetis boasts a Zacks Rank of #3 (Hold).
Looking at valuation, Zoetis is presently trading at a Forward P/E ratio of 27.69. This valuation marks a premium compared to its industry's average Forward P/E of 15.46.
One should further note that ZTS currently holds a PEG ratio of 2.72. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Drugs industry had an average PEG ratio of 1.72 as trading concluded yesterday.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Zoetis (ZTS - Free Report) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.09%. On the other hand, the Dow registered a gain of 1.18%, and the technology-centric Nasdaq increased by 1.03%.
Prior to today's trading, shares of the animal health company had lost 7.46% over the past month. This has lagged the Medical sector's loss of 2.76% and the S&P 500's loss of 0.71% in that time.
Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. In that report, analysts expect Zoetis to post earnings of $1.38 per share. This would mark year-over-year growth of 11.29%. Meanwhile, our latest consensus estimate is calling for revenue of $2.32 billion, up 4.98% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $5.91 per share and a revenue of $9.26 billion, demonstrating changes of +11.09% and +8.41%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.08% increase. At present, Zoetis boasts a Zacks Rank of #3 (Hold).
Looking at valuation, Zoetis is presently trading at a Forward P/E ratio of 27.69. This valuation marks a premium compared to its industry's average Forward P/E of 15.46.
One should further note that ZTS currently holds a PEG ratio of 2.72. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Drugs industry had an average PEG ratio of 1.72 as trading concluded yesterday.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.